Raised midpoint of 2026 financial guidance across revenue, adjusted EBITDA and adjusted EPS
U.S. launch of Gwyn Lo, a low-dose estrogen weekly contraceptive patch, expected later in 2026
U.S. launch of fast-acting meloxicam in acute pain, with management citing up to $500 million in peak sales
Japan regulatory decisions expected in second-half 2026 for pitolisant in obstructive sleep apnea and narcolepsy
Japan NDA submission for Nefecon in IgA nephropathy targeted by end-2026
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Viatris Inc. and 4,900+ companies.